Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo

References

• Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigm Cell Res. 2012;25(3):E1–E13. doi:10.1111/j.1755-148X.2012.00997.x
   Google Scholar
• Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Leprology. 2007;73(3):149.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–491. doi:10.1016/j.jaad.2010.11.06121839315
   PubMed Web of Science ®Google Scholar
• Asem A, Fain PR, Anthony T, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigm Cell Res. 2010;16(3):208–214.
   Google Scholar
• Zhang Z, Xu SX, Zhang FY, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 2009;301(2):167–173. doi:10.1007/s00403-008-0900-z18839195
   PubMed Web of Science ®Google Scholar
• Lerner AB. Part V: clinical applications of psoralens, and related materials: vitiligo. J Invest Dermatol. 1959;32(2):285–310. doi:10.1038/jid.1959.4913641799
   PubMedGoogle Scholar
• Mohammed GF. Highlights in pathogenesis of vitiligo. World J Clin Cases. 2015;3(3):221. doi:10.12998/wjcc.v3.i3.22125789295
   PubMed Web of Science ®Google Scholar
• Ying J, Mailloux CM, Katherine G, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356(12):1216–1225. doi:10.1056/NEJMoa06159217377159
   PubMed Web of Science ®Google Scholar
• Spritz RA. The Genetics of Vitiligo. J Invest Dermatol. 2011;131(E1):E18–E20. doi:10.1038/skinbio.2011.722094401
   PubMedGoogle Scholar
• Zhu KJ, Lv YM, Yin XY, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011;6(11):e23089–e23089. doi:10.1371/journal.pone.002308922125590
   PubMed Web of Science ®Google Scholar
• Wang X, Erf GF. Melanocyte-specific cell mediated immune response in vitiliginous Smyth line chickens. J Autoimmun. 2003;21(2):149–160. doi:10.1016/S0896-8411(03)00087-812935784
   PubMed Web of Science ®Google Scholar
• Slominski A, Paus R, Bomirski A. Hypothesis: possible role for the melatonin receptor in vitiligo: discussion paper. J R Soc Med. 1989;82(9):539–541. doi:10.1177/0141076889082009112552111
   PubMed Web of Science ®Google Scholar
• Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo. Lancet. 2015;386(9988):74–84. doi:10.1016/S0140-6736(14)60763-725596811
   PubMed Web of Science ®Google Scholar
• Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23. doi:10.1126/scitranslmed.3007811
   PubMed Web of Science ®Google Scholar
• Harris JE, Harris TH, Weninger W, et al. A Mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–1876. doi:10.1038/jid.2011.46322297636
   PubMed Web of Science ®Google Scholar
• Gregg RK, Nichols L, Chen Y, et al. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immuno. 2010;184(4):1909–1917. doi:10.4049/jimmunol.0902778
   PubMed Web of Science ®Google Scholar
• Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407. doi:10.1111/pcmr.1221924438589
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Wu J, et al. Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;84(1):e101–e101.
   Google Scholar
• Bassiouny DA, Shaker O. Role of interleukin‐17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292–297. doi:10.1111/j.1365-2230.2010.03972.x21198791
   PubMed Web of Science ®Google Scholar
• Wang CQF, Cruzinigo AE, Fuentesduculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 2011;6(4):e18907–e18907. doi:10.1371/journal.pone.001890721541348
   PubMed Web of Science ®Google Scholar
• Elela MA, Hegazy RA, Fawzy MM, et al. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients. Eur J Dermatol. 2013;23(3):350–355. doi:10.1684/ejd.2013.202323797460
   PubMed Web of Science ®Google Scholar
• Méry‐Bossard L, Bagny K, Chaby G, et al. New‐onset vitiligo and progression of pre‐existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2016;31(1):181–186. doi:10.1111/jdv.1375927291924
   PubMed Web of Science ®Google Scholar
• Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012;132(11):2601–2609. doi:10.1038/jid.2012.18122696056
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol. 1999;4(1):91. doi:10.1038/sj.jidsp.5640189
   Web of Science ®Google Scholar
• Speeckaert R, Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):1–12.27988837
   PubMed Web of Science ®Google Scholar
• Laddha NC, Mitesh D, Mohmmad Shoab M, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 2014;23(5):352–353. doi:10.1111/exd.1237224628992
   PubMed Web of Science ®Google Scholar
• Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013;5(174):ra28. doi:10.1126/scitranslmed.3005127
   Web of Science ®Google Scholar
• Kroll TM, Bommiasamy H, Boissy RE, et al. 4-tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol. 2005;124(4):798. doi:10.1111/j.0022-202X.2005.23653.x15816839
   PubMed Web of Science ®Google Scholar
• Denman CJ, Mccracken J, Hariharan V, et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol. 2008;128(8):2041–2048. doi:10.1038/jid.2008.4518337834
   PubMed Web of Science ®Google Scholar
• Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016;269(1):11–25. doi:10.1111/imr.1236926683142
   PubMed Web of Science ®Google Scholar
• Van GN, Desmedt V, De SS, et al. Cessation of spread as a treatment objective in vitiligo: perception from the patients‘ point of view. Br J Dermatol. 2016;174(4):922. doi:10.1111/bjd.1428326556484
   PubMed Web of Science ®Google Scholar
• Daniel BS, Wittal R. Vitiligo treatment update. Br J Dermatol. 2015;56(2):85–92.
   Google Scholar
• Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999;135(9):1061. doi:10.1001/archderm.135.9.106110490110
   PubMedGoogle Scholar
• Boone B, Ongenae K, Van GN, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007;17(1):55. doi:10.1684/ejd.2007.009317324829
   PubMed Web of Science ®Google Scholar
• Taieb A, Alomar A, BHm M, et al. Guidelines for the management of vitiligo: the European dermatology forum consensus. Br J of Dermatol. 2013;168(1):5–19. doi:10.1111/j.1365-2133.2012.11197.x22860621
   PubMed Web of Science ®Google Scholar
• Veronica L, Benjamin M, Juan Pablo CC, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139(5):581. doi:10.1001/archderm.139.3.36912756094
   PubMedGoogle Scholar
• Iraj E, Ali E, Saeedeh F, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20(1):14–18. doi:10.1080/09546630802155057 18608735
   PubMed Web of Science ®Google Scholar
• Khan R, Satyam A, Gupta S, et al. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res. 2009;301(10):731–737. doi:10.1007/s00403-009-0964-419488773
   PubMed Web of Science ®Google Scholar
• Colucci R, Dragoni F, Conti R, et al. Evaluation of an oral supplement containing Phyllanthus emblica fruit extracts, vitamin E, and carotenoids in vitiligo treatment. Dermatol Ther. 2015;28(1):17–21. doi:10.1111/dth.1217225285994
   PubMed Web of Science ®Google Scholar
• Middelkamp‐Hup MA, Bos JD, Rius‐Diaz F, et al. Treatment of vitiligo vulgaris with narrow‐band UVB and oral Polypodium leucotomos extract: a randomized double‐blind placebo‐controlled study. J Eur Acad Dermatol Venereol. 2007;21(7). doi:10.1111/j.1468-3083.2006.02132.x.
   PubMed Web of Science ®Google Scholar
• Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo – A preliminary study. Dermatol Ther. 2010;23(3):305–307. doi:10.1111/j.1529-8019.2010.01328.x20597950
   PubMed Web of Science ®Google Scholar
• Sunil D, Bhushan K. Repigmentation in vitiligo universalis: role of melanocyte density, disease duration, and melanocytic reservoir. Dermatol Online. 2005;11(3):30.
   Google Scholar
• Kathuria S, Khaitan BK, Ramam M, Sharma V. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2011;78(1):68.
   Web of Science ®Google Scholar
• Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51(1):52–61. doi:10.1016/j.jaad.2003.12.03115243524
   PubMed Web of Science ®Google Scholar
• Lo YH, Cheng GS, Huang CC, et al. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol. 2010;37(2):125–129. doi:10.1111/j.1346-8138.2009.00774.x20175845
   PubMed Web of Science ®Google Scholar
• Nicolaidou E, Antoniou C, Stratigos AJ, et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):0–278. doi:10.1016/j.jaad.2006.09.004
   Web of Science ®Google Scholar
• Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol. 2007;21(7):891–896. doi:10.1111/j.1468-3083.2007.01980.x17658996
   PubMed Web of Science ®Google Scholar
• Roelandts. Photo(chemo) therapy for vitiligo. Photomedicine. 2010;19(1):1–4.
   Google Scholar
• Ghafourian A, Ghafourian S, Sadeghifard N, et al. Vitiligo: symptoms, pathogenesis and treatment. Int J Immunopathol Pharmacol. 2014;27(4):485–489. doi:10.1177/03946320140270040325572727
   PubMed Web of Science ®Google Scholar
• Palmer BC, Delouise L. Nanoparticle enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules. 2016;21(12):1719. doi:10.3390/molecules21121719
   PubMed Web of Science ®Google Scholar
• Marwah H, Garg T, Goyal AK. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2014;23(2):564. doi:10.3109/10717544.2014.93553225006687
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268. doi:10.1038/nbt.150418997767
   PubMed Web of Science ®Google Scholar
• Stinchcomb AL. Editors. Transdermal drug delivery 2nd Edition, revised and expanded (2003) Marcel Dekker,New York 383 pp. J Controlled Release. 2005;104(1):234–235. doi:10.1016/j.jconrel.2004.09.032
   Google Scholar
• Watkinson AC. Transdermal and Topical Drug Delivery Today. Wiley; 2012.
   Google Scholar
• Prausnitz MR, Samir M, Robert L. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3(2):115. doi:10.1038/nrd130415040576
   PubMed Web of Science ®Google Scholar
• Wester RC, Maibach H. In vivo methods for percutaneous absorption measurements. J Toxicol Cutaneous Ocul Toxicol. 2001;20(4):411–422.
   Web of Science ®Google Scholar
• Garg B, Saraswat A, Bhatia A, Katare O. Leprology. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol. 2010;76(3):231. doi:10.4103/0378-6323.6296120445292
   PubMed Web of Science ®Google Scholar
• Franzé S, Donadoni G, Podestà A, et al. Tuning the extent and depth of penetration of flexible liposomes in human skin. Mol Pharm. 2017;14(6):1998. doi:10.1021/acs.molpharmaceut.7b0009928409629
   PubMedGoogle Scholar
• Sinico C, Valenti D, Manconi M, et al. Cutaneous delivery of 8-methoxypsoralen from liposomal and niosomal carriers. J Drug Deliv Sci Technol. 2006;16(2):115–120. doi:10.1016/S1773-2247(06)50017-6
   Web of Science ®Google Scholar
• Mir-Palomo S, Nácher A, Busó OV, et al. Baicalin and berberine ultradeformable vesicles as potential adjuvant in vitiligo therapy. Colloids Surf B Biointerfaces. 2019;175:654–662.30590326
   PubMed Web of Science ®Google Scholar
• Doppalapudi S, Mahira S, Khan W. Development and in vitro assessment of psoralen and resveratrol co-loaded ultradeformable liposomes for the treatment of vitiligo. J Photochem Photobiol B. 2017;174:44–57. doi:10.1016/j.jphotobiol.2017.07.00728753523
   PubMed Web of Science ®Google Scholar
• Jiradej M, Narinthorn K, Friedrich GT, et al. Potent melanin production enhancement of human tyrosinase gene by Tat and an entrapment in elastic cationic niosomes: potential application in vitiligo gene therapy. Chem Biol Drug Des. 2015;80(6):953–960.
   Google Scholar
• Jiradej M, Narinthorn K, Worapaka M, et al. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment. J Pharm Sci. 2010;99(8):3533–3541. doi:10.1002/jps.2210420213835
   PubMed Web of Science ®Google Scholar
• Patel HK, Barot BS, Parejiya PB, et al. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo – part II: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies. Colloids Surf B Biointerfaces. 2014;119(1):145–153.24767976
   PubMedGoogle Scholar
• Patel HK, Barot BS, Parejiya P. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: ex vivo permeation and skin irritation studies. Colloids Surf B Biointerfaces. 2013;102(102):86–94. doi:10.1016/j.colsurfb.2012.08.01123000677
   PubMedGoogle Scholar
• Garg BJ, Garg NK, Beg S, Singh B, Katare OP. Nanosized ethosomes-based hydrogel formulations of methoxsalen for enhanced topical delivery against vitiligo: formulation optimization, in vitro evaluation and preclinical assessment. J Drug Target. 2016;24(3):233–246. doi:10.3109/1061186X.2015.107085526267289
   PubMed Web of Science ®Google Scholar
• Tsuji G, Hashimoto-Hachiya A, Takemura M, et al. Palladium and platinum nanoparticles activate AHR and NRF2 in human keratinocytes-implications in vitiligo therapy. J Invest Dermatol. 2017;137(5):S0022202X17312198. doi:10.1016/j.jid.2017.02.981
   Web of Science ®Google Scholar
• Huang Y, Li Y, Hu Z, et al. Mimicking melanosomes: polydopamine nanoparticles as artificial microparasols. ACS Cent Sci. 2017;3(6):564–569. doi:10.1021/acscentsci.6b0023028691067
   PubMed Web of Science ®Google Scholar
• Wang W, Lu KJ, Yu CH, et al. Nano-drug delivery systems in wound treatment and skin regeneration. J Nanobiotechnology. 2019;17(1):82. doi:10.1186/s12951-019-0514-y31291960
   PubMed Web of Science ®Google Scholar
• Bouwstra JA, Hofland HEJ, Spies F, et al. Changes in the structure of the human stratum corneum induced by liposomes In Braun-Falco O, Korting HC, Maibach HI, editors. Liposome Dermatics. Griesbach Conference. Berlin, Heidelberg: Springer; 1992.
   Google Scholar
• Zhong-Kai C, Anne B, Nicolas C, et al. Formation of pH-sensitive cationic liposomes from a binary mixture of monoalkylated primary amine and cholesterol. Langmuir. 2012;28(38):13668–13674. doi:10.1021/la302278q22931455
   PubMed Web of Science ®Google Scholar
• Pathak MA, Fitzpatrick T. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B. 1992;14(1–2):3–22. doi:10.1016/1011-1344(92)85080-E1432383
   PubMed Web of Science ®Google Scholar
• Wu X, Hu X, Hamblin M. Ultraviolet blood irradiation: is it time to remember “the cure that time forgot”? J Photochem Photobiol B. 2016;157:89–96. doi:10.1016/j.jphotobiol.2016.02.00726894849
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Williams AC, Barry BW. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm. 2000;196(1):63–74. doi:10.1016/S0378-5173(99)00441-X10675708
   PubMed Web of Science ®Google Scholar
• Vidolin AP, Aurizi C, Leone G. Phototherapy for vitiligo, what’s new? G Ital Dermatol Venereol. 2017;152(5):474–488. doi:10.23736/S0392-0488.17.05721-228906087
   PubMed Web of Science ®Google Scholar
• Mir-Palomo S, Nácher A, Díez-Sales O, et al. Inhibition of skin inflammation by baicalin ultradeformable vesicles. Int J Pharm. 2016;511(1):23–29. doi:10.1016/j.ijpharm.2016.06.13627374324
   PubMedGoogle Scholar
• Manconi M, Manca ML, Caddeo C, et al. Nanodesign of new self-assembling core-shell gellan-transfersomes loading baicalin and in vivo evaluation of repair response in skin. Nanomedicine. 2017;14(2):569. doi:10.1016/j.nano.2017.12.00129248674
   PubMed Web of Science ®Google Scholar
• Manconi M, Manca ML, Caddeo C, et al. Preparation of gellan-cholesterol nanohydrogels embedding baicalin and evaluation of their wound healing activity. Eur J Pharmaceutics Biopharmaceutics. 2018;127:S0939641117315382. doi:10.1016/j.ejpb.2018.02.015
   Web of Science ®Google Scholar
• Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie die. 2007;62(2):133–137.
   PubMed Web of Science ®Google Scholar
• Santos P, Watkinson AC, Hadgraft J, Lane M. Application of microemulsions in dermal and transdermal drug delivery. Skin Pharmacol Physiol. 2008;21(5):246. doi:10.1159/00014022818562799
   PubMed Web of Science ®Google Scholar
• Barot BS, Patel HK, Gohel MC, et al. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using d-optimal design. AAPS PharmSciTech. 2012;13(1):184–192. doi:10.1208/s12249-011-9742-722187363
   PubMed Web of Science ®Google Scholar
• Huabing C, Xueling C, Danrong D, Jin L, Huibi X, Xiangliang Y. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2009;315(1):52–58.
   Google Scholar
• Zhao X, Liu JP, Zhang X, et al. Enhancement of transdermal delivery of theophylline using microemulsion vehicle. Int J Pharmaceutics. 2006;327(1):58–64. doi:10.1016/j.ijpharm.2006.07.027
   PubMed Web of Science ®Google Scholar
• Hathout RM, Woodman TJ, Mansour S, et al. Microemulsion formulations for the transdermal delivery of testosterone. Eur J Pharm Sci. 2010;40(3):188–196. doi:10.1016/j.ejps.2010.03.00820304048
   PubMed Web of Science ®Google Scholar
• Patel HK, Barot BS, Parejiya PB, et al. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo–part II: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies. Colloids Surf B Biointerfaces. 2014;119(1):145–153. doi:10.1016/j.colsurfb.2014.02.00524767976
   PubMedGoogle Scholar
• Valenzuela P, Simon JAJN. Nanoparticle delivery for transdermal HRT. Nanomedicine. 2012;8(1):S83–S89. doi:10.1016/j.nano.2012.05.00822640909
   PubMedGoogle Scholar
• Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes–a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Sci Pharm. 2003;29(9):1013–1026.
   Google Scholar
• Yoko Y, Ayumi H, Qing-Li Z, et al. Protective effects of platinum nanoparticles against UV-light-induced epidermal inflammation. Small. 2010;19(11):1000–1006.
   Google Scholar
• Shibuya S, Ozawa Y, Yokote K, et al. 209–palladium and platinum nanoparticles attenuate aging-like skin atrophy via antioxidant activity. PLoS One. 2014;76(10):S90–S90.
   Google Scholar
• Kobayashi H, Kumagai K, Eguchi T, et al. Characterization of T cell receptors of th1 cells infiltrating inflamed skin of a novel murine model of palladium-induced metal allergy. PLoS One. 2013;8(10):e76385. doi:10.1371/journal.pone.007638524098486
   PubMed Web of Science ®Google Scholar
• Sun L, Liu Z, Cun D, HY Tong, Zheng Y. Application of nano- and micro-particles on the topical therapy of skin-related immune disorders. Curr Pharm Des. 2015;21(19):2643–2667.25876913
   PubMed Web of Science ®Google Scholar
• Ashtikar M, Nagarsekar K, Fahr A. Transdermal delivery from liposomal formulations - Evolution of the technology over the last three decades. J Controlled Release. 2016;242:126. doi:10.1016/j.jconrel.2016.09.008
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies. J Controlled Release. 2008;127(1):59–69. doi:10.1016/j.jconrel.2007.12.013
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Sharma V, Pathak K. Pilosebaceous targeting by isotretenoin loaded invasomal gel for the treatment of eosinophilic pustular folliculitis: optimization, efficacy and cellular analysis. Drug Dev Ind Pharm. 2016;43(2):293–304. doi:10.1080/03639045.2016.123962827649797
   PubMed Web of Science ®Google Scholar
• Chen M, Liu X, Fahr A. Skin delivery of ferulic acid from different vesicular systems. J Biomed Nanotechnol. 2010;6(5):577–585. doi:10.1166/jbn.2010.115421329050
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, et al. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Controlled Release. 2000;65(3):403–418. doi:10.1016/S0168-3659(99)00222-9
   PubMed Web of Science ®Google Scholar
• Cevc G. Preparation for drug application in minute droplet form. 1996.
   Google Scholar
• Ma G, Wu C. Microneedle, bio-microneedle and bio-inspired microneedle: a review. J Controlled Release. 2017;251(Complete):11–23. doi:10.1016/j.jconrel.2017.02.011
   PubMedGoogle Scholar
• Cai X, Yang X, Wang F, et al. Multifunctional pH-responsive folate receptor mediated polymer nanoparticles for drug delivery. J Biomed Nanotechnol. 2016;12(7):1453. doi:10.1166/jbn.2016.228729337470
   PubMed Web of Science ®Google Scholar
• Lim HJ, Kim JK, Park J, et al. Complexation of apoptotic genes with polyethyleneimine (PEI)-Coated Poly-(DL)-Lactic-Co-Glycolic acid nanoparticles for cancer cell apoptosis. J Biomed Nanotechnol. 2015;11(2):211. doi:10.1166/jbn.2015.188026349297
   PubMed Web of Science ®Google Scholar
• Ribeiro N, Costa-Pinheiro P, Henrique R, et al. Comprehensive analysis of secreted protein, acidic and rich in cysteine in prostate carcinogenesis: development of a 3D nanostructured bone-like model. J Biomed Nanotechnol. 2016;12(8):1667. doi:10.1166/jbn.2016.227629342345
   PubMed Web of Science ®Google Scholar
• Liu X, Li X, Zhang N, et al. Bioengineering strategies for the treatment of type i diabetes. J Biomed Nanotechnol. 2016;12(4):581. doi:10.1166/jbn.2016.217627301187
   PubMed Web of Science ®Google Scholar
• Yu H, Tang Z, Li M, et al. Cisplatin Loaded Poly (L-glutamic acid)-g-Methoxy Poly(ethylene glycol) complex nanoparticles for potential cancer therapy: preparation, in vitro and in vivo evaluation. J Biomed Nanotechnol. 2016;12(1):69. doi:10.1166/jbn.2016.215227301173
   PubMed Web of Science ®Google Scholar
• Votavova P, Tomala J, Subr V, et al. Novel IL-2-Poly (HPMA)nanoconjugate based immunotherapy. J Biomed Nanotechnol. 2015;11(9):1662. doi:10.1166/jbn.2015.211426485935
   PubMed Web of Science ®Google Scholar
• Hu B, Liu X, Zhang C, et al. Food macromolecule based nanodelivery systems for enhancing the bioavailability of polyphenols. J Food Drug Anal. 2017;25(1):3. doi:10.1016/j.jfda.2016.11.00428911541
   PubMed Web of Science ®Google Scholar
• Kim CS, Ahn YC, Wilder P, Oh S, Chen Z, Kwon YJ. Efficient and facile delivery of gold nanoparticles in vivo using dissolvable microneedles for contrast-enhanced optical coherence tomography. Biomed Opt Express. 2010;1(1):106–113. doi:10.1364/BOE.1.00010621258450
   PubMed Web of Science ®Google Scholar
• Gratieri T, Kalia Y. Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier. Adv Drug Deliv Rev. 2013;65(2):315–329. doi:10.1016/j.addr.2012.04.01222626977
   PubMed Web of Science ®Google Scholar
• Byrne JD, Yeh JJ, JM D. Use of iontophoresis for the treatment of cancer. J Controlled Release. 2018;284:144–151. doi:10.1016/j.jconrel.2018.06.020
   PubMed Web of Science ®Google Scholar
• Vutla NB, Betageri GV, Banga AK. Transdermal iontophoretic delivery of enkephalin formulated in liposomes. J Pharm Sci. 1996;85(1):5–8. doi:10.1021/js950349y8926583
   PubMed Web of Science ®Google Scholar
• Hama S, Kimura Y, Mikami A, et al. Electric stimulus opens intercellular spaces in skin. J Biol Chem. 2014;289(4):2450–2456. doi:10.1074/jbc.M113.51441424318878
   PubMed Web of Science ®Google Scholar
• Wolf Horrell Erin M, Boulanger Mary C, D’Orazio John A. Melanocortin 1 receptor: structure, function, and regulation. Front Genet. 2016;7:95.27303435
   PubMed Web of Science ®Google Scholar
• Lahav R. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol. 2005;49(2–3):173–180. doi:10.1016/j.colsurfb.2018.12.05515906230
   PubMed Web of Science ®Google Scholar
• Hirobe T, Shinpo T, Higuchi K, et al. Life cycle of human melanocytes is regulated by endothelin-1 and stem cell factor in synergy with cyclic AMP and basic fibroblast growth factor. J Dermatol Sci. 2010;57(2):123–131. doi:10.1016/j.jdermsci.2009.11.00620045284
   PubMed Web of Science ®Google Scholar
• Boissy RE. Melanosome transfer to and translocation in the keratinocyte. Exp Dermatol. 2003;12(s2):5–12. doi:10.1034/j.1600-0625.12.s2.1.x
   PubMedGoogle Scholar
• Nystedt S, Emilsson K, Larsson AK, et al. Molecular cloning and functional expression of the gene encoding the human proteinase‐activated receptor 2. Eur J Biochem. 1995;232(1). doi:10.1111/j.1432-1033.1995.tb20784.x.
   PubMedGoogle Scholar
• Bohm SK, Kong W, Bromme D, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996;314(3):1009–1016. doi:10.1042/bj31410098615752
   PubMedGoogle Scholar
• Jung H, Oh ES. FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression. Pigment Cell Melanoma Res. 2016;29(4):434–443. doi:10.1111/pcmr.1248027060922
   PubMed Web of Science ®Google Scholar
• Jung H, Chung H, Chang SE, et al. FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. Pigment Cell Melanoma Res. 2016;29(2):199–209. doi:10.1111/pcmr.1244326581186
   PubMed Web of Science ®Google Scholar
• Wijnen RMH, Ericzon BG, Tiebosch ATMG, et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int. 1992;5(Suppl 1):S454–S458. doi:10.1111/tri.1992.5.s1.45414621844
   PubMedGoogle Scholar
• Tzu JH, Utine CA, Stern ME, et al. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea. 2012;31(6):649–654. doi:10.1097/ICO.0b013e31822481c222378107
   PubMed Web of Science ®Google Scholar
• Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm. 2013;79(1):0–94.
   Web of Science ®Google Scholar
• Eberle AN. Proopiomelanocortin and the Melanocortin Peptides. Humana Press; 2000.
   Google Scholar
• Semenza G. The melanotropins: chemistry, physiology and mechanisms of action. FEBS Lett. 1989;242:449–450. doi:10.1016/0014-5793(89)80523-X
   Google Scholar
• Lipton J. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today. 1997;18:140–145. doi:10.1016/S0167-5699(97)01009-89078687
   PubMedGoogle Scholar
• Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofactors. 2009;35(2):193–199. doi:10.1002/biof.2919449448
   PubMed Web of Science ®Google Scholar
• Parsad D, Dogra S, Kanwar A. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1(1):58. doi:10.1186/1477-7525-1-5814613564
   PubMedGoogle Scholar
• Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 2011;25(1):9–13. doi:10.1111/j.1755-148X.2011.00939.x22099450
   PubMed Web of Science ®Google Scholar
• Seow WY, Salgado G, Lane EB, Hauser CA. Transparent crosslinked ultrashort peptide hydrogel dressing with high shape-fidelity accelerates healing of full-thickness excision wounds. Sci Rep. 2016;6:32670. doi:10.1038/srep3267027600999
   PubMed Web of Science ®Google Scholar
• Chan KH, Xue B, Robinson RC, et al. Systematic moiety variations of ultrashort peptides produce profound effects on self-assembly, nanostructure formation, hydrogelation, and phase transition. Sci Rep. 2017;7(1):12897. doi:10.1038/s41598-017-12694-929018249
   PubMedGoogle Scholar
• Kiat HC, Wei HL, Ming N, et al. C-terminal residue of ultrashort peptides impacts on molecular self-assembly, hydrogelation, and interaction with small-molecule drugs. Sci Rep. 2018;8:1–14.29311619
   PubMed Web of Science ®Google Scholar